KM Research Hub
← 返回论文库
已完成 入排:排除 图源:可得 入排置信度 0.90

Health-related quality of life in patients with aggressive non-Hodgkin lymphoma: results from the PETAL trial.

Ulrich Dührsen, Gabriele Prange-Krex, Regina Moeller, Harald Held, Gerhard Heil, Andreas Schwarzer, Stefan Mahlmann, Ariane Dienst, Matthias Sandmann, Georg Maschmeyer, Jochen Schütte, Dennis Hahn, Michael Heike, Michael Nonnemacher, Christine Hanoun, Andreas Hüttmann, PETAL trial investigators

Ann Hematol 104(5) 2831-2845

PMID40397196
PMCIDPMC12141138
DOI10.1007/s00277-025-06402-1
发表日期2025-05-21
入排依据:This is an original result report from a randomized Phase III trial in oncology with a drug intervention, but it analyzes health-related quality of life as the primary/key secondary endpoint, not a time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR). Therefore, it is excluded.
摘要

摘要

When different therapies provide similar cure rates, health-related quality of life (HRQoL) may become crucial for the choice of treatment. In the Positron Emission Tomography-guided Therapy of Aggressive non-Hodgkin Lymphomas (PETAL) trial, we compared six cycles of R-CHOP with or without two extra doses of rituximab in prognostically favorable interim PET (iPET)-negative patients, while eight cycles of R-CHOP were compared with two R-CHOP cycles followed by six cycles of a more intensive protocol in prognostically unfavorable iPET-positive patients. As reported previously, treatment intensification did not improve outcome. HRQoL was assessed using the EORTC QLQ-C30 questionnaire. Pretreatment questionnaires were obtained from 558 out of the 862 participants (64.7%). Pretreatment HRQoL was significantly worse than in the general population. It was associated with age, gender, B symptoms, International Prognostic Index (IPI) and total metabolic tumor volume (TMTV). Physical and cognitive functioning predicted survival independent of IPI or TMTV. During treatment, some domains remained stable (e.g., cognitive functioning, nausea/vomiting), while others improved (e.g., emotional functioning, pain) or deteriorated (e.g., physical functioning, role functioning, fatigue). At the end of treatment, HRQoL was better in patients with controlled disease than in patients with progressive disease and better for iPET-negative patients than for iPET-positive patients. During follow-up, all HRQoL domains returned to levels similar to those reported for the general population. Differences between randomized treatment arms were not observed. The longitudinal data need to be interpreted with caution, because decreasing participation resulted in a selection of patients with increasingly good outcomes. ClinicalTrials.gov no. NCT00554164 (registered 11/5/2007).

KM 提取结果

2 个 Figure · 10 个 KM 面板

进入结果中心
KM Figure4 个面板

Fig. 2

Fig. 2 Progression-free survival (top) and overall survival (bottom) in relation to physical (left) or cognitive functioning (right) at the pretreatment quality-of-life assessment. Low, patients with scores below or equal to the median of all observed scores; high, patients with scores above the median. HR, hazard ratio; CI, confidence interval; p, log-rank test (cf. text for HR, CI and p adjusted for the covariates lymphoma subtype and International Prognostic Index)

Physical_functioning_-_Progression-free_survival

Progression-free survival

Fig. 2 · Panel Physical_functioning_-_Progression-free_survival

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel Physical_functioning_-_Progression-free_survival 是同一 Fig. 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
Cognitive_functioning_-_Progression-free_survival

Progression-free survival

Fig. 2 · Panel Cognitive_functioning_-_Progression-free_survival

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel Cognitive_functioning_-_Progression-free_survival 是同一 Fig. 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
Physical_functioning_-_Overall_survival

Overall survival

Fig. 2 · Panel Physical_functioning_-_Overall_survival

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel Physical_functioning_-_Overall_survival 是同一 Fig. 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
Cognitive_functioning_-_Overall_survival

Overall survival

Fig. 2 · Panel Cognitive_functioning_-_Overall_survival

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel Cognitive_functioning_-_Overall_survival 是同一 Fig. 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
KM Figure6 个面板

Fig. 5

Fig. 5 Progression-free survival in relation to completion versus non-completion of the quality-of-life questionnaire before treatment (top), at end of treatment (middle) and after 12 months of follow-up (bottom). Left, interim PET negative patients (good prognosis); right, interim PET positive patients (poor prognosis). HR, hazard ratio; CI, confidence interval; p, log-rank test

Interim_PET_negative_Baseline_assessment

Progression-free survival

Fig. 5 · Panel Interim_PET_negative_Baseline_assessment

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel Interim_PET_negative_Baseline_assessment 是同一 Fig. 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
Interim_PET_positive_Baseline_assessment

Progression-free survival

Fig. 5 · Panel Interim_PET_positive_Baseline_assessment

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel Interim_PET_positive_Baseline_assessment 是同一 Fig. 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
Interim_PET_negative_End-of-treatment_assessment

Progression-free survival

Fig. 5 · Panel Interim_PET_negative_End-of-treatment_assessment

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel Interim_PET_negative_End-of-treatment_assessment 是同一 Fig. 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
Interim_PET_positive_End-of-treatment_assessment

Progression-free survival

Fig. 5 · Panel Interim_PET_positive_End-of-treatment_assessment

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel Interim_PET_positive_End-of-treatment_assessment 是同一 Fig. 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
Interim_PET_negative_12-month_follow-up_assessment

Progression-free survival

Fig. 5 · Panel Interim_PET_negative_12-month_follow-up_assessment

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel Interim_PET_negative_12-month_follow-up_assessment 是同一 Fig. 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
Interim_PET_positive_12-month_follow-up_assessment

Progression-free survival

Fig. 5 · Panel Interim_PET_positive_12-month_follow-up_assessment

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel Interim_PET_positive_12-month_follow-up_assessment 是同一 Fig. 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Fig. 1 Global quality of life (left) and fatigue (right) at the pretreatment quality-of-life assessment in relation to the International Prognostic Index (top) or ascending quartiles of the total metabolic tumor volume (bottom). Cf. Table 2 for numbers of patients; p, Kruskal–Wallis test
非 KM Figure
Fig. 3Fig. 3 Four patterns of quality-of-life changes during treatment and follow-up. Top left, no change; top right, rapid improvement; bottom left, delayed improvement; bottom right, initial deterioration with subsequent improvement. Higher scores denote better performance. Cf. Table 3 for numbers of patients; iPET, interim positron emission tomography (before treatment cycle 3); EoT, 3–6 weeks after the end of treatment; 3-m, 6-m, 9-m and 12-m FU, 3-, 6-, 9- and 12-month follow-up; p, Kruskal–Wallis test
非 KM Figure
Fig. 4Fig. 4 Functioning (top) and symptoms (bottom) at the end-of-treatment (EoT) quality-of-life assessment in relation to the interim PET response. Negative interim PET response, 299 patients; positive interim PET response, 28 patients. Note that higher scores denote better performance in the functional scales, while higher scores represent worse performance in the symptom scales. p, Kruskal–Wallis test
非 KM Figure